Literature DB >> 8612857

High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome.

J A Land1, M I Yarmolinskaya, J C Dumoulin, J L Evers.   

Abstract

OBJECTIVE: To study the outcome in poor responders to three ampules (225 IU) of hMG per day in subsequent IVF treatment cycles in which six ampules (450 IU)of hMG per day were administered.
DESIGN: Retrospective chart review.
SETTING: Academic tertiary center. PATIENTS: Between January 1988 and May 1995, 126 poor response patients had a first treatment cycle on three ampules and a second cycle on six ampules of hMG per day. MAIN OUTCOME MEASURES: Numbers of follicles, oocytes, and embryos, and pregnancy rates.
RESULTS: On six ampules, patients had significantly more follicles and oocytes. The number of embryos did not differ significantly. The pregnancy rate on six ampules were low (3.2% pregnancies per cycle started).
CONCLUSION: Poor responders do not benefit from high-dose hMG stimulation; their reproduction outcome is poor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612857     DOI: 10.1016/s0015-0282(16)58269-7

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  34 in total

1.  Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders.

Authors:  Pu-Tsui Wang; Robert Kuo-kuang Lee; Jin-Tsung Su; Jen-Wan Hou; Ming-Huei Lin; Yu-Ming Hu
Journal:  J Assist Reprod Genet       Date:  2002-01       Impact factor: 3.412

2.  A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI.

Authors:  Eric H M Hoomans; Bernard B Mulder
Journal:  J Assist Reprod Genet       Date:  2002-10       Impact factor: 3.412

3.  Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization.

Authors:  Eun Mi Chang; Ji Eun Han; Hyung Jae Won; You Shin Kim; Tae Ki Yoon; Woo Sik Lee
Journal:  J Assist Reprod Genet       Date:  2011-12-08       Impact factor: 3.412

4.  Mean ovarian diameter (MOD) as a predictor of poor ovarian response.

Authors:  Iavor K Vladimirov; Desislava M Tacheva; Krassimir B Kalinov
Journal:  J Assist Reprod Genet       Date:  2004-03       Impact factor: 3.412

Review 5.  Is there a recommended maximum starting dose of FSH in IVF?

Authors:  Luk Rombauts
Journal:  J Assist Reprod Genet       Date:  2007-06-17       Impact factor: 3.412

6.  Effect of micro-vibration culture system on embryo development.

Authors:  Yong Soo Hur; Jeong Hyun Park; Eun Kyung Ryu; Sung Jin Park; Jun Ho Lee; Soo Hee Lee; Jung Yoon; San Hyun Yoon; Chang Young Hur; Won Don Lee; Jin Ho Lim
Journal:  J Assist Reprod Genet       Date:  2013-05-09       Impact factor: 3.412

7.  Meta-analysis of GnRH-antagonists versus GnRH-agonists in poor responder protocols.

Authors:  Myrto Papamentzelopoulou; Sofoklis Stavros; Despoina Mavrogianni; Christos Kalantzis; Dimitrios Loutradis; Petros Drakakis
Journal:  Arch Gynecol Obstet       Date:  2021-01-10       Impact factor: 2.344

8.  Superovulation with a high gonadotropin dose for in vitro fertilization: is it effective?

Authors:  H Lashen; W Ledger; A López Bernal; B Evans; D Barlow
Journal:  J Assist Reprod Genet       Date:  1998-08       Impact factor: 3.412

9.  The need to step up the gonadotropin dosage in the stimulation phase of IVF treatment predicts a poor outcome.

Authors:  D L Hock; H Louie; R M Shelden; C V Ananth; E Kemmann
Journal:  J Assist Reprod Genet       Date:  1998-08       Impact factor: 3.412

10.  The clinical analysis of poor ovarian response in in-vitro-fertilization embryo-transfer among Chinese couples.

Authors:  X M Zhen; J Qiao; R Li; L N Wang; P Liu
Journal:  J Assist Reprod Genet       Date:  2008-01-18       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.